Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Aprepitant and cytarabine composition and an anti-leukemia effect thereof

A technology of cytarabine and aprepitant, which can be used in drug combinations, medical preparations containing active ingredients, anti-tumor drugs, etc., can solve the problems of nervous system and organ effects, serious toxic and side effects, etc.

Pending Publication Date: 2020-09-11
ZHEJIANG SCI-TECH UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although large doses of cytarabine have obvious therapeutic effects, but the side effects are very serious, including serious effects on the nervous system and organs [22]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aprepitant and cytarabine composition and an anti-leukemia effect thereof
  • Aprepitant and cytarabine composition and an anti-leukemia effect thereof
  • Aprepitant and cytarabine composition and an anti-leukemia effect thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0040] 1. Materials and Methods

[0041] 1.1 Materials, Reagents and Instruments

[0042] 1.1.1 Materials

[0043] Human acute myeloid leukemia cells HL60 were donated by the First Affiliated Hospital of Zhejiang University School of Medicine. Aprepitant and cytarabine were purchased from Beijing Suolaibao Technology Co., Ltd.

[0044] 1.1.2 Main reagents

[0045]

[0046]

[0047] 1.1.3 Reagent preparation

[0048] (1) Phosphate buffer saline (PBS): accurately weigh 0.2g potassium chloride, 8g sodium chloride, 0.24g potassium dihydrogen phosphate and 3.63g disodium hydrogen phosphate dodecahydrate with an electronic balance, add Wash the rotor with secondary water, dissolve it in the secondary water with a magnetic stirrer, adjust the pH to 7.4, and set the volume to 1000mL. After dispensing, sterilize under high temperature and high pressure at 121°C for 20 minutes, and then store at 4°C. .

[0049] (2) Aprepitant: make a 30 mM mother solution with DMSO and store...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to aripiptan and cytarabine composition and an anti-leukemia effect thereof, in particular to a method for treating leukemia in a subject, relieving leukemia symptoms inthe subject or inhibiting proliferation of leukemia cells. The method comprises the step of administering aripiptan combined with cytarabine to subjects. Further, the invention relates to a leukemia treatment drug. The drug comprises aripiptan and cytarabine, and an optional pharmaceutically acceptable carrier.

Description

technical field [0001] The invention relates to the anticancer effect of aprepitant combined with cytarabine. Specifically related to: a method for treating cancer in a subject, relieving cancer symptoms in a subject, or inhibiting the proliferation of cancer cells in a combined drug; Use in medicaments; and pharmaceutical products for the treatment of cancer. Background technique [0002] As one of the diseases with the highest morbidity and mortality in the world, cancer is rapidly growing worldwide and is a major global public health problem [1] . Epidemiological statistics show that leukemia accounts for 2.4% and 3.2% of global cancer morbidity and mortality, respectively, and is showing an increasing trend year by year [2] . Acute myeloid leukemia (AML) is a malignant disease of the bone marrow, characterized by clonal expansion and differentiation arrest of myeloid progenitor cells, and AML is the most common form of acute leukemia in adults, with a five-year survi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7068A61K31/5377A61P35/02
CPCA61K31/5377A61K31/7068A61P35/02A61K2300/00
Inventor 付彩云黄飞燕吴鸿章程旭锐
Owner ZHEJIANG SCI-TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com